Processa Pharmaceuticals, Inc. (PCSA) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to Processa Pharmaceuticals' fourth quarter and year-end 2021 earnings conference call and corporate update. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If you have a question or a comment, please hit star 1 on your touchtone phone. Pressing star 2 will remove you from the queue should your question be answered. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. Thank you, sir. You may begin. Thank you and welcome to Processa's fourth quarter and year-end 2021 results and drug development update conference call. Joining me on the call today are our Chief Executive Officer, Dr. David Young, and our Chief Operating Officer, Mike Floyd. Shortly before this call, we filed our 2021 annual report on Form 10-K. I want to remind everyone that a PowerPoint presentation will accompany Dr. Young's prepared remarks. To view the PowerPoint slides, please go to the investor relations section of the company's website or our earnings press release and click on the webcast link to follow along. I will start our call by reading the safe harbor statement. This statement is made pursuant to the safe harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. All statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although we believe expectations and assumptions reflected in these forward-looking statements are reasonable, we can make no assurances that such expectations will prove to be correc...